GM24589
Fibroblast from Skin, Skin
Description:
USHER SYNDROME, TYPE IIC; USH2C
Repository
|
NIGMS Human Genetic Cell Repository
|
Subcollection |
Heritable Diseases PIGI Consented Sample |
Biopsy Source
|
Skin
|
Cell Type
|
Fibroblast
|
Tissue Type
|
Skin
|
Transformant
|
Untransformed
|
Sample Source
|
Fibroblast from Skin, Skin
|
Race
|
White
|
Ethnicity
|
Ashkenazic Jewish
|
Country of Origin
|
USA
|
Family Member
|
1
|
Family History
|
Y
|
Relation to Proband
|
proband
|
Confirmation
|
Molecular characterization before cell line submission to CCR
|
Species
|
Homo sapiens
|
Common Name
|
Human
|
Remarks
|
|
PDL at Freeze |
6.16 |
Passage Frozen |
2 |
|
IDENTIFICATION OF SPECIES OF ORIGIN |
Species of Origin Confirmed by LINE assay |
|
Gene |
GPR98 |
Chromosomal Location |
5q14.3 |
Allelic Variant 1 |
; |
Identified Mutation |
c.8801C>A |
|
Gene |
GPR98 |
Chromosomal Location |
5q14.3 |
Allelic Variant 2 |
; |
Identified Mutation |
c.14973-2A>G; Novel splice site mutation. |
Remarks |
Clinically affected; symptom onset at age 3; diagnosed at age 21; retinitis pigmentosa; hearing loss; subject has 2 mutations in the GPR98 (VLGR1) gene: c.8801C>A (S2934X), novel nonsense mutation in exon 39 and c.14973-2A>G, a novel splice site mutation in intron 73; assistive devices/treatments: hearing aid, speech language therapy; father is GM24590, mother is GM24591. |
Cumulative PDL at Freeze |
6.16 |
Passage Frozen |
2 |
Split Ratio |
1:7 |
Temperature |
37 C |
Percent CO2 |
5% |
Percent O2 |
3% |
Medium |
Eagle's Minimum Essential Medium with Earle's salts and non-essential amino acids with 2mM L-glutamine or equivalent |
Serum |
15% fetal bovine serum Not inactivated |
Supplement |
- |
|
|